DNAM-1/CD226 Antibody [Alexa Fluor™ Plus 555]

• Clonality: Polyclonal
• Host: Goat
• Conjugate: Alexa Fluor Plus 555

DNAM-1/CD226 Antibody [Alexa Fluor™ Plus 555] Summary

• Specificity: Detects human DNAM-1/CD226 in direct ELISAs and Western blots.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for DNAM-1/CD226 Antibody [Alexa Fluor™ Plus 555]

• CD226 antigenplatelet and T cell activation antigen 1
• CD226 molecule
• CD226
• DNAM1
• DNAM-1
• DNAM1adhesion glycoprotein
• DNAM-1DNAX accessory molecule-1
• DNAX accessory molecule 1
• PTA1
• T lineage-specific activation antigen 1 antigen
• TLiSA1

Background

DNAX accessory molecule-1 (DNAM-1), also known as CD226, is a 65 kDa type I transmembrane glycoprotein in the immunoglobulin superfamily (1). Mature human DNAM-1 contains a 236 amino acid (aa) extracellular domain (ECD) with two Ig-like C2-set domains and a 61 aa cytoplasmic region that contains motifs for binding PDZ domains and band 4.1 family proteins (1, 2). Within the ECD, human DNAM-1 shares 50% and 52% aa sequence identity with mouse and rat DNAM-1, respectively. DNAM-1 is expressed on multiple lymphoid and myeloid cells and interacts with CD155/PVR and Nectin-2/CD112 (3, 4). Ligation of DNAM-1 promotes the activation of NK cells, CD8⁺ T cells, and mast cells (2‑6), dendritic cell maturation, megakaryocyte and activated platelet adhesion to vascular endothelial cells, and monocyte extravasation; it inhibits the forrmation of osteoclasts (7‑10). Platelet-endothelium interactions mediated by DNAM-1 enable the metastasis of tumor cells to the lung (11). In activated, but not in resting NK, T, and mast cells, the cis association of DNAM-1 with CD18 contributes to the tyrosine and serine phosphorylation of DNAM-1 during activation (6, 9, 12‑14).

1. Fuchs, A. and M. Colonna (2006) Semin. Cancer Biol. 16:359.
2. Shibuya, A. et al. (1996) Immunity 4:573.
3. Bottino, C. et al. (2003) J. Exp. Med. 198:557.
4. Tahara-Hanaoka, S. et al. (2004) Int. Immunol. 16:533.
5. Dardalhon, V. et al. (2005) J. Immunol. 175:1558.
6. Bachelet, I. et al. (2006) J. Biol. Chem. 281:27190.
7. Reymond, N. et al. (2004) J. Exp. Med. 199:1331.
8. Kakehi, S. et al. (2007) Mol. Cell. Biochem. 301:209.
9. Kojima, H. et al. (2003) J. Biol. Chem. 278:36748.
10. Tahara-Hanaoka, S. et al. (2006) Blood 107:1491.
11. Morimoto, K. et al. (2007) Oncogene July 16 epub.
12. Shibuya, K. et al. (1999) Immunity 11:615.
13. Shibuya, K. et al. (2003) J. Exp. Med. 198:1829.
14. Shibuya, A. et al. (1998) J. Immunol. 166:1671.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.